BioRestorative Therapies, Inc.
Nasdaq · Healthcare · Services-Misc Health & Allied Services, Nec · Melville, NY
BRTX chart
What traders are saying about $BRTX
Latest postsBioRestorative Therapies, Inc. news
- BioRestorative Therapies Announces Reverse Stock Split
Yahoo Finance ·
- Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
Yahoo Finance ·
- BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform
Yahoo Finance ·
- BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth
Yahoo Finance ·
- Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)
Yahoo Finance ·
- BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data
Yahoo Finance ·
- What Makes Biorestorative Therapies (BRTX) a New Buy Stock
Yahoo Finance ·
- Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates
Yahoo Finance ·
- BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals
Yahoo Finance ·
- PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates
Yahoo Finance ·
- BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease
Yahoo Finance ·
- BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform
Yahoo Finance ·
BioRestorative Therapies, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $359,700 | $401,000 | $145,800 | $119,800 |
| Net income | -$14.2M | -$9.0M | -$10.4M | -$13.2M |
| Diluted EPS | $-1.58 | $-1.16 | $-2.47 | $-3.65 |
| Total assets (year end) | $4.1M | $12.3M | $12.6M | $16.4M |
| Cash and equivalents (year end) | $1.5M | $547,890 | $884,377 | $1.7M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About BioRestorative Therapies, Inc.
- Ticker
- BRTX (Nasdaq)
- Industry
- Services-Misc Health & Allied Services, Nec
- Headquarters
- Melville, NY
- Incorporated in
- NV
- Fiscal year end
- December 31
- SEC CIK
- 1505497
- Former names
- Stem Cell Assurance, Inc.
Frequently asked questions
What exchange is BioRestorative Therapies, Inc. listed on?
BioRestorative Therapies, Inc. trades on the Nasdaq under the ticker symbol BRTX.
What industry is BioRestorative Therapies, Inc. in?
BioRestorative Therapies, Inc. is classified by the SEC under "Services-Misc Health & Allied Services, Nec", part of the Healthcare sector on StockTweeting.
Where is BioRestorative Therapies, Inc. headquartered?
BioRestorative Therapies, Inc.'s business address on file with the SEC is in Melville, NY.
When does BioRestorative Therapies, Inc.'s fiscal year end?
BioRestorative Therapies, Inc.'s fiscal year ends on December 31.
How much revenue did BioRestorative Therapies, Inc. report?
BioRestorative Therapies, Inc. reported $359,700 in revenue for calendar year 2025, according to its SEC filings.